Boston Scientific Announces Results For First Quarter 2021
News provided by
Share this article
Share this article
MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational
1 basis and 5.9 percent on an organic
2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $327 million or $0.23 per share (EPS), compared to GAAP net income of $11 million or $0.01 per share a year ago, and achieved adjusted EPS of $0.37 for the period, compared to $0.28 a year ago.
Operator
Good morning and welcome to the Boston Scientific First Quarter 2021 Financial Results Conference Call. [Operator Instructions]
I would now like to turn the conference over to Susan Lisa, Vice President, Investor Relations. Please go ahead.
Susie Lisa
Vice President, Investor Relations
Thank you, Andrew. Good morning everyone and thanks for joining us. With me on today s call are Mike Mahoney, Chairman and Chief Executive Officer and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q1 2021 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release, as well as reconciliations of the non-GAAP measures used in today s call, to the Investor Relations section of our website under the heading Financials and Filings.
TRESTLE Compliance Reports Impressive Financial Growth on 4th Anniversary
BOSTON, MA / ACCESSWIRE / April 21, 2021 / TRESTLE Compliance, a highly-specialized, privately-held, boutique compliance consulting firm providing a full spectrum of compliance, privacy, risk and regulatory services to assist businesses in the life sciences sector, today announced its 4th anniversary and an exceptional growth year, marked with a number of high-level accomplishments in 2020 and 2021.
Among the most notable milestones for TRESTLE this year:
Fourth Anniversary: Celebrating its fourth anniversary, the Company is furthering its reach in and beyond the Boston biotech hub, to include New York City, Chicago, Orange County, CA, Utah, and the UK; this multi-disciplined team of professionals with 20+ years of expertise, creates custom, precise, and properly scaled compliance and privacy solutions for life sciences companies.
Share:
NEW YORK, April 21, 2021 /PRNewswire/ Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners on Monday, April 26, 2021 at 11:00 Eastern.
Mr. Kidron, along with Premas Biotech Co-Founder and Managing Director Dr. Prabuddha Kundu, will discuss Oramed Pharmaceuticals oral insulin drug, currently in Phase 3 clinical trials, and the oral COVID-19 vaccine candidate of Oravax Medical Inc., which is 63% owned by Oramed Pharmaceuticals. Pre-clinical trials have shown that Oravax s oral vaccine candidate produces antibodies after a single dose and may potentially be a better candidate for
Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners Grand Rounds: A Webinar in Biotech and Specialty Pharma prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.